| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Laura Brege is Director at PCRX and has filed Form 4s across 3 companies. From February 2015 to June 2026, the filings on record show 2 open-market purchases and 13 sales. Laura Brege's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.9M at current prices.
Historically, Laura Brege's trades have earned a middling insider score of 58/100 across 7 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +16.1%.
The biggest single holding is MIRM (~$1.4M) as Director. The MIRM filings lean toward selling, a net 7,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2019 | MIRM Mirum Pharmaceuticals, Inc. | Director | Buy | 10,000 | $11.22 | $112,200.00 | New | |
| Jan 9, 2019 | ACAD Acadia Pharmaceuticals Inc | Director | Sale+OE | 10,000 | $20.00 | $200,041.00 | - | |
| Jan 2, 2018 | ACAD Acadia Pharmaceuticals Inc | Director | Sale+OE | 25,000 | $30.06 | $751,542.50 | - | |
| Jun 6, 2016 | PCRX Pacira Biosciences, Inc. | Director | Sell | 1,000 | $46.95 | $46,950.00 | -50.0% | |
| Feb 11, 2015 | ACAD Acadia Pharmaceuticals Inc | Director | Sale+OE | 10,000 | $33.63 | $336,349.00 | - |